drugset / Trial / NCT02630108

Summary

It is a prospective and multi-center clinical research in China to compare the efficacy, safety and related impact factors between TACE alone and TACE combined with synchronous multi-point MWA/RFA for large and huge liver cancer.

Timeline

Start
2015-12
Primary completion
2017-12
Completion
2018-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background EADM Unknown 30 mg
Background EADM Unknown 60 mg
Background lipiodol Unknown 38 %